CGIX up +16.83% percent Today $CGIX High is at 7.94 and the

New Post Public Reply Private Reply Replies (0) Message Board

Nov 10, 2014 at 2:44 PM

CGIX up +16.83% percent Today $CGIX High is at 7.94 and the Low 6.76 with current volume of 164,713.

Recent News posted below.

Cancer Genetics Inc CGIX other info.
http://investorshangout.com/Cancer-Genetics-Inc-CGIX-88009/

CGIX Cancer Genetics Inc Recent Headline News

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - 1 hr 44 mins ago

UCP: 11.90 (-1.89), JRJC: 6.24 (+0.73), NAVB: 1.02 (-0.20), SANW: 3.83 (+0.75), PLPM: 1.63 (+0.26), RYN: 28.81 (-5.09), INFU: 3.00 (-0.49), LIOX: 5.46 (+0.72), DY: 27.77 (-3.10), MTZ: 25.15 (-3.48), CGIX: 6.90 (+0.90), MUX: 1.25 (-0.16), OREX: 5.10 (+1.25), URRE: 2.59 (+0.65), ACHN: 12.51 (+2.40), REN: 2.83 (-0.78), MPO: 3.34 (+0.23), AKBA: 9.39 (-1.31), TRX: 1.02 (-0.20), PLNR: 7.53 (+1.13)

Cancer Genetics' (CGIX) CEO Panna Sharma on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - 2 hrs 15 mins ago

CGIX: 6.90 (+0.90)

Cancer Genetics ups revenues 88% in Q3
Seeking Alpha - at Seeking Alpha - 2 hrs 40 mins ago

CGIX: 6.90 (+0.90)

Cancer Genetics Announces Strong Third Quarter With Growth Across All Categories
GlobeNewswire - Mon Nov 10, 7:43AM CST
Cancer Genetics, Inc. (Nasdaq:CGIX), an emerging leader in DNA-based cancer diagnostics, announced today financial and operating results for the third quarter ended September 30, 2014.
CGIX: 6.90 (+0.90)

Cancer Genetics beats by $0.07, beats on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 6:58AM CST

CGIX: 6.90 (+0.90)

Cancer Genetics, Inc. to Report Third Quarter 2014 Financial Results on Monday, November 10
GlobeNewswire - Thu Oct 30, 7:30AM CDT
Cancer Genetics, Inc. (Nasdaq:CGIX), an emerging leader in DNA-based cancer diagnostics, announced today that it will report third quarter 2014 financial results on Monday, November 10, 2014. The Company will issue a press release before the market opens and will host a conference call at 8:30am Eastern Standard Time to discuss the third quarter financial results and to answer questions.
CGIX: 6.90 (+0.90)

Cancer Genetics Inc. Granted Patent for Genomic Probe Set Used in Proprietary Test for Cervical and Other HPV-Associated Cancers
GlobeNewswire - Tue Oct 21, 6:59AM CDT
> Issuance of patent 8,865,882 covers four probe set used in CGI's proprietary FISH-based HPV-Associated Cancer Test (FHACT(R))
CGIX: 6.90 (+0.90)

Cancer Genetics Inc. Announces Collaboration With Leading Oncology Researchers at Columbia University to Identify Genomic Signatures, Biomarkers and Novel Treatments for MDS and AML
GlobeNewswire - Mon Oct 13, 6:45AM CDT
> The collaboration will result in a novel, next-generation sequencing based panel for the improved diagnosis and prognosis of Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
CGIX: 6.90 (+0.90)

Global Genetic Testing Market - Industry Analysis And Market Forecast 2014-2020
PR Newswire - Thu Oct 09, 2:50PM CDT
Genetic testing is the analysis of genes, chromosomes, or proteins to help predict the risk of disease, identify carriers (individuals who do not have the disease but have a copy of the disease gene) of disease, diagnose disease, or determine the likely course of a disease. Cytogenetics, Molecular Genetics, Cancer Genetics, Prenatal Screening and Prenatal diagnosis are type of genetic tests that involves examining a person's genetic material taken from cells in a sample of blood or, occasionally, from other body fluids or tissues.
CGIX: 6.90 (+0.90)

Cancer Genetics Inc. to Provide Updates About the Company's Portfolio of Targeted Molecular Diagnostics at Analyst Day on September 25, 2014
GlobeNewswire - Wed Sep 24, 6:45AM CDT
Cancer Genetics Inc. (Nasdaq:CGIX) ("CGI" or "the Company"

, an emerging leader in DNA-based cancer diagnostics, today released an agenda for its upcoming Analyst Day, to be held Thursday, September 25 in Raleigh, North Carolina.
CGIX: 6.90 (+0.90)

Cancer Genetics, Inc. and Beth Israel Deaconess Medical Center Enter Into Collaboration to Correlate Genomic Profiles to Patient Outcome in Diffuse Large B-Cell Lymphoma
GlobeNewswire - Tue Sep 23, 6:45AM CDT
-- Study will correlate genetic markers to outcome in ~200 patients with diffuse large B-cell lymphoma (DLBCL), the most common form of non-Hodgkin lymphoma.
CGIX: 6.90 (+0.90)

Cancer Genetics, Inc. to Present at Aegis Healthcare and Technology Conference on Thursday, September 11, 2014
GlobeNewswire - Wed Sep 10, 6:59AM CDT
Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or "The Company"

, an emerging leader in DNA-based cancer diagnostics, announced today that Panna Sharma will present at the Aegis Healthcare and Technology Conference on Thursday, September 11, 2014 at 8:30 am Pacific Daylight Time (11:30 am EDT).
CGIX: 6.90 (+0.90)

Cancer Genetics' Proprietary IVD for Cervical Cancer, FHACT(R), Receives CE
GlobeNewswire - Tue Sep 02, 7:15AM CDT
- Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or "The Company"

, an emerging leader in DNA-based cancer diagnostics, announced today that their proprietary DNA-probe based test for cervical cancer (FHACT(R)) has received the CE Marking.
CGIX: 6.90 (+0.90)

Cancer Genetics' Proprietary Genomic Diagnostic Tests Added to National Institutes of Health's Genetic Testing Registry
GlobeNewswire - Wed Aug 27, 6:59AM CDT
-- Online database allows clinicians and patients to search for genetic and genomic tests by disease state
CGIX: 6.90 (+0.90)

Cancer Genetics, Inc. and Leading Pathologist From Keck Medicine of USC Collaborate to Evaluate and Optimize Genomic Panel for Lymphoma
GlobeNewswire - Mon Aug 25, 7:30AM CDT
-- Collaboration will identify and evaluate new genomic markers for most common form of non-Hodgkin's lymphoma
CGIX: 6.90 (+0.90)

Cancer Genetics Inc. Completes Acquisition of BioServe India, a Premier Genomics and Next-Generation Sequencing Company
GlobeNewswire - Sun Aug 17, 11:00PM CDT
-- Cancer Genetics Now Positioned to Participate in High-Growth Indian Diagnostics Market, Where More Than 1 Million New Cancer Cases Are Diagnosed Each Year
CGIX: 6.90 (+0.90)

Cancer Genetics Reports Second Quarter 2014 Financial Results
GlobeNewswire - Thu Aug 14, 6:05AM CDT
Cancer Genetics, Inc. (Nasdaq:CGIX), an emerging leader in DNA-based cancer diagnostics, announced today financial results for the second quarter and six months ended June 30, 2014.
CGIX: 6.90 (+0.90)

BioNano Genomics Announces The Purchase Of The Irys System By The Wellcome Trust Sanger Institute
PR Newswire - Tue Aug 12, 7:00AM CDT
BioNano Genomics announced today the purchase of an IrysTM System by the Wellcome Trust Sanger Institute, one of the world's leading genome centers, located near Cambridge, UK. The Sanger Institute made the largest single contribution to the gold standard sequence for the Human Genome Project and today is focused on the role of genetics in health and disease. The Sanger Institute purchased BioNano's Irys platform to detect structural variation and complete genomes for various projects including the Cancer Genomics Project, which seeks to develop new ways of detecting rearrangements in cancer samples, and the Parasite Genomics Team, which is sequencing the genomes of parasites that cause malaria and neglected tropical diseases prevalent in the developing world.
CGIX: 6.90 (+0.90)

Cancer Genetics to Report Second Quarter 2014 Financial Results on Thursday, August 14, 2014
GlobeNewswire - Fri Aug 08, 7:56AM CDT
Cancer Genetics, Inc. (Nasdaq:CGIX), an emerging leader in DNA-based cancer diagnostics, announced today that it will report second quarter 2014 financial results on Thursday, August 14, 2014. The Company will issue a press release before the market opens and will host a conference call at 8:30am Eastern Time to discuss the second quarter financial results, the closing of the Gentris acquisition, the proposed FDA regulatory framework, and to answer questions.
CGIX: 6.90 (+0.90)

RedChip Issues Research Update on Cancer Genetics
GlobeNewswire - Thu Aug 07, 11:09AM CDT
RedChip Companies, Inc., today announced it has issued a research profile on Cancer Genetics, Inc. (Nasdaq:CGIX), an emerging leader in DNA-based cancer diagnostics that personalizes the clinical management of difficult-to-diagnose cancers.
CGIX: 6.90 (+0.90)

Vyant Bio, Inc. (VYNT) Stock Research Links

VYNT Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Advenica: Rising Star in Secure File Transfer Market

Advenica's Ascent in Secure File Transfer The cybersecurity world never sleeps, and with the rapid pace of digital threats, it's no surprise that secure file transfer solutions are becoming hotter commodities than coffee pots on Wall Street. Advenica, a name that might not ring a bell for everyone, has emerged as an 'Emerging Leader' in MarketsandMarkets' latest...

KuCoin's KCUSD Tackles Stablecoin Idle Capital Problem

KuCoin's Bold Move with KCUSD Folks, the cat's outta the bag with KuCoin's latest maneuver—introducing KCUSD. At first glance, it seems like they're just introducing another fancy stablecoin product, but peel the onion and there's more to it. We're talking about shaking up how stablecoins sit tight doing nada in the crypto world. KCUSD is out to make those idle balances...

Europe's Largest Carbon Capture Facility Launches

A New Chapter in Industrial Decarbonization Today's not just your average ribbon-cutting ceremony; it's a landmark turn in our journey toward a cleaner Europe. Yara's Sluiskil plant in the Netherlands just fired up Europe's biggest carbon capture facility, marking a crucial pivot point in industrial decarbonization. We're talking about capturing a staggering 800,000 tons...

Sungrow's MGTL Series: A Game-Changer in Solar Tech

Smarter Energy Systems Are Here Gone are the days when solar inverters were just clunky bits of tech you threw on a roof. Sungrow's latest MGTL Series, revealed in Da Nang, marks a revolutionary step for Southeast Asia, Africa, Latin America, and beyond. They're not just talking the talk—they're bringing real innovation to the table. Why the MGTL Series Stands Out Look,...

Snack Bars Market to Hit $32.66B by 2031: Growth and Challenges

Snack Bars Navigate a Transforming Market There's a headwind in the snack bars market as it looks to lift off from $21.94 billion and land at $32.66 billion by 2031. That's a solid climb at an 8.28% CAGR. What's fueling this leap? A desire for convenient, portable nutrition that's squeezing into every nook of modern life—from the gym to the car, to your kid's lunchbox....

Michigan Roof Inspections: Seasonal Insights That Count

Weather's Wrath and the Michigan Roof Here's the deal: Michigan doesn't mess around when it comes to weather. We're talking harsh winters with piles of snow, followed by muggy summers that toss storms like they're confetti. Keeping that roof in top shape isn't just some luxury; it’s a downright necessity. Gut-punch reality? Many ignore it until it's too late. That's...

53% of European Telecom Users Eye Provider Switch

Change Is Brewing in Europe's Telecom Markets Seems like Europe's telco scene is simmering. Over half of consumers in major European markets are giving their mobile providers the side-eye, ready to jump ship. That's putting the heat on operators who once banked on loyalty programs to keep their customer base intact. Diverse Loyalty Challenges Across Europe What's...

Overpricing in Atlanta Luxury Real Estate: Risks & Rewards

When Pricing Sends the Wrong Message Jump into the high stakes poker game of Atlanta's luxury real estate, and you'll find that pricing strategy is your make-or-break move. Jud Whitlock, a seasoned veteran over at Atlanta Fine Homes/Sotheby's International Realty, lays it all down: in this digital age, pricing too high is akin to waving a red flag at savvy buyers armed...

Thermoplastic Polyimide: A $0.86 Billion Market by 2032

It's not often you get hyped about a compound with a name like 'thermoplastic polyimide,' but hold your horses—this isn't just any chemical. If you're watching markets with a sharp eye, you’ll see this thing estimated at $0.56 billion in 2026, gunning for a hefty $0.86 billion by 2032. We're talking about a solid 7.4% CAGR ride here folks, according to new data from...

DNOW Faces Class Action: Proxy Missteps Under Fire

DNOW's Rough Patch: Investors, Beware Here's a tangled mess for you: DNOW Inc., a name that should've been cruising post-merger, now finds itself smack in the middle of a class action lawsuit. Blame it on some botched acquisition moves with MRC Global Inc. The suits claim DNOW's management may have played fast and loose with the truth during their big merger spiel. When...